vs
CB Financial Services, Inc.（CBFV）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是CB Financial Services, Inc.的1.4倍（$19.6M vs $13.8M），CB Financial Services, Inc.同比增速更快（19.9% vs -11.5%），CB Financial Services, Inc.自由现金流更多（$17.2M vs $-23.1M），过去两年CB Financial Services, Inc.的营收复合增速更高（1.2% vs -12.2%）
CB银行是缅甸规模最大的商业银行之一，也是缅甸首家发行ATM卡与信用卡的银行。该银行由吴钦貌艾担任董事长、吴觉杜哥担任首席执行官，在缅甸全国拥有超过245家分支机构，是缅甸本土市场布局广泛的主流金融机构。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CBFV vs LAB — 直观对比
营收规模更大
LAB
是对方的1.4倍
$13.8M
营收增速更快
CBFV
高出31.3%
-11.5%
自由现金流更多
CBFV
多$40.2M
$-23.1M
两年增速更快
CBFV
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.8M | $19.6M |
| 净利润 | — | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 38.1% | -168.5% |
| 净利率 | — | -177.4% |
| 营收同比 | 19.9% | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益（稀释后） | $0.90 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBFVLAB
| Q4 25 | $13.8M | — | ||
| Q3 25 | $2.4M | $19.6M | ||
| Q2 25 | $13.5M | $21.8M | ||
| Q1 25 | $12.1M | $40.8M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $12.7M | $22.1M | ||
| Q2 24 | $12.2M | $22.5M | ||
| Q1 24 | $13.5M | $45.5M |
净利润CBFVLAB
| Q4 25 | — | — | ||
| Q3 25 | $-5.7M | $-34.7M | ||
| Q2 25 | $3.9M | $-33.5M | ||
| Q1 25 | $1.9M | $-26.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.2M | $-26.9M | ||
| Q2 24 | $2.6M | $-45.7M | ||
| Q1 24 | $4.2M | $-32.2M |
毛利率CBFVLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率CBFVLAB
| Q4 25 | 38.1% | — | ||
| Q3 25 | -289.8% | -168.5% | ||
| Q2 25 | 35.0% | -118.1% | ||
| Q1 25 | 19.3% | -80.8% | ||
| Q4 24 | 23.1% | — | ||
| Q3 24 | 31.2% | -120.9% | ||
| Q2 24 | 26.4% | -134.5% | ||
| Q1 24 | 37.9% | -132.2% |
净利率CBFVLAB
| Q4 25 | — | — | ||
| Q3 25 | -235.2% | -177.4% | ||
| Q2 25 | 29.3% | -153.7% | ||
| Q1 25 | 15.8% | -63.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.3% | -122.0% | ||
| Q2 24 | 21.8% | -203.3% | ||
| Q1 24 | 31.1% | -70.6% |
每股收益（稀释后）CBFVLAB
| Q4 25 | $0.90 | — | ||
| Q3 25 | $-1.07 | $-0.09 | ||
| Q2 25 | $0.74 | $-0.09 | ||
| Q1 25 | $0.35 | $-0.07 | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.60 | $-0.07 | ||
| Q2 24 | $0.51 | $-0.12 | ||
| Q1 24 | $0.82 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.7M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $157.5M | $399.7M |
| 总资产 | $1.5B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBFVLAB
| Q4 25 | $31.7M | — | ||
| Q3 25 | $55.9M | $129.4M | ||
| Q2 25 | $64.5M | $158.6M | ||
| Q1 25 | $61.3M | $150.9M | ||
| Q4 24 | $49.6M | — | ||
| Q3 24 | $147.3M | $210.6M | ||
| Q2 24 | $142.6M | $269.8M | ||
| Q1 24 | $73.7M | $287.1M |
总债务CBFVLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CBFVLAB
| Q4 25 | $157.5M | — | ||
| Q3 25 | $152.5M | $399.7M | ||
| Q2 25 | $148.4M | $424.5M | ||
| Q1 25 | $148.3M | $454.6M | ||
| Q4 24 | $147.4M | — | ||
| Q3 24 | $149.1M | $489.3M | ||
| Q2 24 | $142.9M | $510.3M | ||
| Q1 24 | $141.6M | $577.3M |
总资产CBFVLAB
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | $539.6M | ||
| Q2 25 | $1.5B | $557.0M | ||
| Q1 25 | $1.5B | $579.6M | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | $681.5M | ||
| Q2 24 | $1.6B | $708.7M | ||
| Q1 24 | $1.5B | $777.7M |
负债/权益比CBFVLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.8M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $17.2M | $-23.1M |
| 自由现金流率自由现金流/营收 | 124.1% | -118.1% |
| 资本支出强度资本支出/营收 | 4.7% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $29.5M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CBFVLAB
| Q4 25 | $17.8M | — | ||
| Q3 25 | $4.6M | $-22.2M | ||
| Q2 25 | $4.1M | $-20.7M | ||
| Q1 25 | $4.0M | $-30.3M | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $3.1M | $-27.9M | ||
| Q2 24 | $-1.2M | $-39.0M | ||
| Q1 24 | $3.3M | $-62.5M |
自由现金流CBFVLAB
| Q4 25 | $17.2M | — | ||
| Q3 25 | $4.5M | $-23.1M | ||
| Q2 25 | $3.9M | $-22.6M | ||
| Q1 25 | $3.9M | $-35.3M | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $2.2M | $-30.1M | ||
| Q2 24 | $-2.4M | $-41.0M | ||
| Q1 24 | $2.3M | $-63.3M |
自由现金流率CBFVLAB
| Q4 25 | 124.1% | — | ||
| Q3 25 | 186.5% | -118.1% | ||
| Q2 25 | 28.8% | -103.6% | ||
| Q1 25 | 32.5% | -86.6% | ||
| Q4 24 | 26.0% | — | ||
| Q3 24 | 17.4% | -136.4% | ||
| Q2 24 | -19.6% | -182.2% | ||
| Q1 24 | 17.0% | -138.9% |
资本支出强度CBFVLAB
| Q4 25 | 4.7% | — | ||
| Q3 25 | 4.3% | 4.5% | ||
| Q2 25 | 1.9% | 8.7% | ||
| Q1 25 | 0.8% | 12.4% | ||
| Q4 24 | 25.1% | — | ||
| Q3 24 | 6.7% | 10.2% | ||
| Q2 24 | 10.0% | 8.6% | ||
| Q1 24 | 7.2% | 1.7% |
现金转化率CBFVLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBFV
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
